Barbara Gayle Duncan, Chief Financial Officer at INTERCEPT PHARMACEUTICALS INC (ICPT), sold 936 shares at $145.90 ($137K) on 2016-01-04, disclosed to the SEC on 2016-01-05.
Open-market sale of $137k ICPT by Chief Financial Officer. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Something here stands out, but not much.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $145.90 | 40 | $6K | 4.3% |
| 2 | $145.90 | 428 | $62K | 45.7% |
| 3 | $145.90 | 40 | $6K | 4.3% |
| 4 | $145.90 | 428 | $62K | 45.7% |
| Total | $145.90 avg | 936 | $137K | 100% |
| Filing → |
| JNCE | SELL | 2018-01-29 | $100K | — | Filing → |
| GNMX | BUY | 2017-10-18 | $150K | — | Filing → |
| ICPT | SELL | 2016-10-05 | $24K | — | Filing → |